No Data
Sage Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Express News | Sage Therapeutics Inc : RBC Raises to Sector Perform From Underperform
TD Cowen Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $9
H.C. Wainwright Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $14
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Strategic Shifts
Express News | Sage Therapeutics Shares Reverse Course; Last up 4.3%
No Data
No Data